Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12063
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMertens, Laura Sen
dc.contributor.authorMir, M Carmenen
dc.contributor.authorScott, Andrew Men
dc.contributor.authorLee, Sze Tingen
dc.contributor.authorFioole-Bruining, Annemarieen
dc.contributor.authorVegt, Eriken
dc.contributor.authorVogel, Wouter Ven
dc.contributor.authorManecksha, Rustomen
dc.contributor.authorBolton, Damien Men
dc.contributor.authorDavis, Ian Den
dc.contributor.authorHorenblas, Simonen
dc.contributor.authorvan Rhijn, Bas W Gen
dc.contributor.authorLawrentschuk, Nathanen
dc.date.accessioned2015-05-16T01:42:32Z
dc.date.available2015-05-16T01:42:32Z
dc.date.issued2014-02-01en
dc.identifier.citationUrology; 83(2): 393-8en
dc.identifier.govdoc24468513en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12063en
dc.description.abstractTo investigate the association between extravesical (18)F-fluorodeoxyglucose (FDG) avid lesions on FDG-positron emission tomography/computed tomography (PET/CT) and mortality in patients with muscle-invasive bladder cancer.An international, bi-institutional cohort study of 211 patients with muscle-invasive bladder cancer who underwent staging CT and FDG-PET/CT imaging. On the basis of the presence of extravesical FDG-avid lesions suspicious for malignancy on PET/CT images, patients were divided into a PET/CT-positive and PET/CT-negative group. Data on staging and mortality were retrospectively analyzed from prospective databases. Kaplan-Meier analyses were performed to compare overall (OS) and disease-specific survival (DSS) between the groups. Multivariable Cox regression models were used to investigate the association between extravesical PET/CT lesions and mortality. Extravesical lesions suspicious for malignancy on conventional CT were included in the models.Of the 211 patients, 98 (46.4%) had 1 or more extravesical lesions on PET/CT, 113 (53.5%) had a negative PET/CT. Conventional CT revealed extravesical lesions in 51 patients (24.4%). Median follow-up was 18 months. Patients with a positive PET/CT had a significantly shorter OS and DSS (median OS: 14 vs 50 months, P = .001; DSS: 16 vs 50 months, P <.001). In multivariable analysis, the presence of extravesical lesions on PET/CT was an independent prognostic indicator of mortality (OS: hazard ratio = 3.0, confidence interval 95% 1.7-5.1). This association was not statistically significant for conventional CT (hazard ratio = 1.6 (95% confidence interval 0.9-2.7).On the basis of our results, the presence of extravesical FDG-avid lesions on PET/CT might be considered an independent indicator of mortality.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherCohort Studiesen
dc.subject.otherFemaleen
dc.subject.otherFluorodeoxyglucose F18.diagnostic useen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMultimodal Imagingen
dc.subject.otherMuscle, Smoothen
dc.subject.otherNeoplasm Invasivenessen
dc.subject.otherNeoplasm Stagingen
dc.subject.otherPositron-Emission Tomographyen
dc.subject.otherPredictive Value of Testsen
dc.subject.otherPrognosisen
dc.subject.otherRadiopharmaceuticals.diagnostic useen
dc.subject.otherRetrospective Studiesen
dc.subject.otherTomography, X-Ray Computeden
dc.subject.otherUrinary Bladder Neoplasms.diagnosis.mortality.pathologyen
dc.title18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleUrologyen
dc.identifier.affiliationDepartment of Medicine, Ludwig Institute for Cancer Research, University of Melbourne and Center for PET, Austin Hospital, Melbourne, Australiaen
dc.identifier.affiliationJoint Medical Oncology Unit, Austin Hospital, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Surgery, Ludwig Institute for Cancer Research, University of Melbourne and Center for PET, Austin Hospital, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlandsen
dc.identifier.affiliationDepartment of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.en
dc.identifier.affiliationDepartment of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.en
dc.identifier.affiliationDepartment of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.en
dc.identifier.doi10.1016/j.urology.2013.10.032en
dc.description.pages393-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24468513en
dc.type.austinJournal Articleen
local.name.researcherBolton, Damien M
item.languageiso639-1en-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

52
checked on Jan 3, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.